Hypothyroidism is the most common endocrinopathy related to immunotherapy, and its incidence is reported as 13.2% with combination therapy, 7.0% with anti-PD-1 therapy, and similar rates for ipilimumab and anti-PD-L1 alone of 3.8% and 3.9%, respectively. Here, PDCD1 is linked to hypothyroidism.